Sagimet Biosciences (SGM) announced entry into a license agreement with Assia Chemical Industries, doing business as TAPI Technology & API Services, a subsidiary of Teva Pharmaceutical (TEVA). Under the agreement, TAPI has granted Sagimet a global, exclusive license to certain intellectual property rights covering innovative forms of TAPI’s resmetirom active pharmaceutical ingredient for Sagimet’s technical evaluation and manufacture, and, if elected by Sagimet, further development of a fixed-dose combination product containing denifanstat and resmetirom. Pending patent applications filed by Sagimet and TAPI cover the FDC and the innovative resmetirom forms, respectively.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva price target raised to $35 from $28 at JPMorgan
- Insider Selling Frenzy: AppLovin, Teva, AST SpaceMobile, MongoDB, and Western Digital Stocks in Focus!
- Teva Pharmaceutical Extends Revolving Facility Agreement
- FTC investigation prompts Teva request for removal of patents from Orange Book
- Teva price target raised to $32 from $29 at BofA